Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Bone Joint Surg Am ; 94(9): 786-93, 2012 May 02.
Article in English | MEDLINE | ID: mdl-22552667

ABSTRACT

BACKGROUND: Platelet-rich plasma is reported to contain multiple growth factors, and has been utilized in orthopaedic surgery to aid healing in multiple tissues. To date, the use of autologous platelet-rich plasma has not been studied for its effects on normal soft tissue. METHODS: Eighteen adult New Zealand White rabbits were injected with 0.5 mL of autologous platelet-rich plasma in the right or left quadriceps muscle, Achilles tendon, medial collateral ligament, subcutaneous tissue, tibial periosteum, and ankle joint. Saline solution was injected on the contralateral side as a control. The soft tissues were examined histologically at two weeks (six rabbits) and six weeks (six rabbits), and soft tissues from six rabbits that had been reinjected at six weeks were examined at twelve weeks. RESULTS: Inflammatory skin lesions were visible at forty-eight hours at superficial platelet-rich plasma sites. All lesions resolved by six days. Compared with findings in control specimens, histological analysis of platelet-rich plasma injection sites at two weeks showed a marked inflammatory infiltrate with lymphocytic and monocytic predominance. Intra-articular injection showed villous synovial hyperplasia and chronic synovitis. Tendon and ligament sites showed new collagen deposition. Intramuscular injection sites showed thrombosis, necrosis, and calcium deposition. Subcutaneous sites also showed calcium deposition without necrosis as well as collagen nodules representing early scar tissue. Histological examination of platelet-rich plasma injection sites at six and twelve weeks demonstrated a persistent but diminished inflammatory infiltrate. Focal areas of scar tissue were seen with fibroblasts, collagen formation, and neovascularity. All saline solution sites at all times were nonreactive. CONCLUSIONS: Platelet-rich plasma can initiate an inflammatory response in the absence of an inciting injury in normal soft tissue in rabbits.


Subject(s)
Achilles Tendon/drug effects , Connective Tissue/drug effects , Joint Capsule/drug effects , Medial Collateral Ligament, Knee/drug effects , Muscle, Skeletal/drug effects , Platelet-Rich Plasma , Achilles Tendon/pathology , Animals , Ankle Joint , Biological Products/pharmacology , Connective Tissue/pathology , Injections , Joint Capsule/pathology , Male , Medial Collateral Ligament, Knee/pathology , Muscle, Skeletal/pathology , Rabbits , Tibia
2.
J Biomed Mater Res B Appl Biomater ; 82(2): 460-70, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17245749

ABSTRACT

COLLOSS and COLLOSS E are osteoinductive bone void fillers consisting of bone collagen and noncollagenous proteins from bovine and equine bone, respectively. The aim of this study was to compare COLLOSS, COLLOSS E, iliac bone autograft, sintered beta tricalcium phosphate (beta-TCP; OSSAPLAST), and COLLOSS E plus OSSAPLAST. Materials were placed for 4, 8, or 24 weeks in 5-mm cortical bone defects in sheep long bones. Histological sections in a plane perpendicular to the long axis of the bone were used to measure the total repair area (original defect plus callus) and the area of bone within the total repair area. The incidence of defect union was also evaluated. At 4 and 8 weeks, defects treated with COLLOSS and COLLOSS E with or without OSSAPLAST had total repair and bone areas equivalent to autograft, and larger than OSSAPLAST-treated defects. At 8 weeks, the incidence of defect union was higher in defects treated with autograft or COLLOSS E plus OSSAPLAST than in untreated defects. At 24 weeks, the incidence of union was 100% in all treatment groups and 0% in untreated defects. The incidence of union was related to the degree of remodeling between 8 and 24 weeks. This was greater in all treated than nontreated defects. In conclusion, COLLOSS and COLLOSS E were equivalent to each other and to autograft, and superior to beta-TCP, in this study model.


Subject(s)
Bone Morphogenetic Proteins/administration & dosage , Bone Regeneration/drug effects , Bone Substitutes/administration & dosage , Calcium Phosphates/administration & dosage , Collagen/administration & dosage , Tibia/drug effects , Animals , Female , Ilium/transplantation , Sheep, Domestic , Tibia/cytology , Tibia/injuries , Transplantation, Autologous
3.
J Cell Physiol ; 208(3): 566-74, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16741990

ABSTRACT

The secosteroid hormone 1alpha, 25-dihydroxyvitamin D3 (1,25D) has been shown to regulate the growth and differentiation of human prostate cancer (PCa) cells, although the precise molecular mechanisms mediating these effects have not been defined. Previous studies in our laboratory demonstrated that the antiproliferative effects of 1,25D on PCa cells are mediated through the nuclear vitamin D receptor (VDR). In the present study, we performed gene profiling of LNCaP human PCa cells following 1,25D treatment and identified the antitumorigenic gene, prostate derived factor (PDF), as being highly induced by 1,25D. PDF is a member of the TGF-beta superfamily and has been implicated in a variety of functions directly related totumorigenicity including antiproliferative and pro-apoptotic effects. Gene expression studies using 1,25D analogs and a VDR antagonist demonstrate that 1,25D-mediated induction of PDF message and protein in PCa cells is dependent on VDR action. PDF is a transcriptional target of the tumor suppressor, p53. Here we show that the expression of PDF in nine PCa cell lines is dependent on functional p53. Additionally, transfection of p53-null ALVA-31 PCa cells with a p53 expression plasmid, and expression of dominant negative p53 in LNCaP PCa cells, show that the ability of VDR to induce PDF requires functional p53. Importantly, forced PDF expression in PC-3 cells results in decreased cell proliferation, soft agar cloning, and xenograft tumor size. These data demonstrate that PDF exerts antitumorigenic properties on PCa cells and its regulation by 1,25D may provide insights into the action of 1,25D in PCa.


Subject(s)
Bone Morphogenetic Proteins/genetics , Calcitriol/pharmacology , Gene Expression Regulation, Neoplastic/drug effects , Prostatic Neoplasms/genetics , Tumor Suppressor Protein p53/physiology , Animals , Cell Division/drug effects , Cell Line, Tumor , DNA Primers , Growth Differentiation Factor 15 , Humans , Male , Oligonucleotide Array Sequence Analysis , Promoter Regions, Genetic , Prostatic Neoplasms/pathology , RNA, Neoplasm/genetics , RNA, Neoplasm/isolation & purification , Rats , Rats, Nude , Transcriptional Activation , Transplantation, Heterologous , Tumor Suppressor Protein p53/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...